Literature DB >> 22434733

Interferon regulatory factor-1 as a positive regulator for high glucose-induced proliferation of vascular smooth muscle cells.

Sun Yu1, Zhang Xi, Chen Hai-Yan, Chi Ya-Li, Xiong Shao-Hu, Zhang Chuan-Sen, Yang Xiang-Qun, Guo Jin-Ping, Lin Hai-Yan, Dong Lei.   

Abstract

High glucose-induced proliferation of vascular smooth muscle cells (VSMCs) plays an important role in the development of diabetic vascular diseases. However, molecular mediators responding for the proliferation of VSMCs remain to be determined. In this study, VSMCs were isolated from the rat thoracic aorta, and two cell models with Irf-1 knockdown and overexpression were established by transfecting cells with pGCsi-FU-Irf-1 and pGC-FU-Irf-1, respectively. Subsequently, high glucose was added to cells to induce proliferation. Proliferation assays were performed to see whether Irf-1 was involved in high glucose-induced proliferation of VSMCs. In addition, the expression of Irf-1 was detected in VSMCs stimulated with high glucose and the thoracic aorta of diabetic rats to confirm the relationship between Irf-1 expression and the proliferation of hyperglycemia-dependent VSMCs. The results showed that Irf-1 expression was significantly higher in the thoracic aorta of diabetic rats and VSMCs stimulated with high glucose than that in nondiabetic rats and untreated cells. Overexpression of Irf-1 accelerated the proliferation of VSMCs, and down-regulation of Irf-1 expression significantly depressed the proliferative ability of VSMCs under high-glucose conditions, indicating that Irf-1 was a positive regulator for high glucose-induced proliferation of VSMCs. It could be presumed that Irf-1 is associated with the accelerated proliferation of VSMCs in diabetic vascular diseases and may prove to be a potential target gene for disease treatment.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434733     DOI: 10.1002/jcb.24142

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Upregulation of Interferon Regulatory Factor 6 Promotes Neuronal Apoptosis After Traumatic Brain Injury in Adult Rats.

Authors:  Yuchang Lin; Dezhi Xu; Xiaohong Li; Chun Liu; Xia Liu; Shen Huang; Yuwei Huang; Xiaojuan Liu
Journal:  Cell Mol Neurobiol       Date:  2015-06-16       Impact factor: 5.046

2.  CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction.

Authors:  Balachandar Venkatesan; Anthony J Valente; Nitin A Das; Andrea J Carpenter; Tadashi Yoshida; Jean-Luc Delafontaine; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2012-10-17       Impact factor: 4.315

3.  Interferon regulatory factor-1 together with reactive oxygen species promotes the acceleration of cell cycle progression by up-regulating the cyclin E and CDK2 genes during high glucose-induced proliferation of vascular smooth muscle cells.

Authors:  Xi Zhang; Long Liu; Chao Chen; Ya-Li Chi; Xiang-Qun Yang; Yan Xu; Xiao-Tong Li; Shi-Lei Guo; Shao-Hu Xiong; Man-Ru Shen; Yu Sun; Chuan-Sen Zhang; Kai-Meng Hu
Journal:  Cardiovasc Diabetol       Date:  2013-10-14       Impact factor: 9.951

4.  Differential regulation of human aortic smooth muscle cell proliferation by monocyte-derived macrophages from diabetic patients.

Authors:  Te-Chuan Chen; Mao-Ling Sung; Hsing-Chun Kuo; Shao-Ju Chien; Chia-Kuang Yen; Cheng-Nan Chen
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

5.  Identification of Transcription Regulatory Relationships in Diabetic Nephropathy.

Authors:  Jing-Song Shi; Dan-Dan Qiu; Wei-Bo Le; Hui Wang; Shen Li; Yin-Hui Lu; Song Jiang
Journal:  Chin Med J (Engl)       Date:  2018-12-05       Impact factor: 2.628

6.  Sitagliptin attenuates high glucose-induced alterations in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells through ERK1/2 signal pathway.

Authors:  Lili Shi; Ye Ji; Dandan Liu; Ying Liu; Ying Xu; Yang Cao; Xiaoyan Jiang; Changqing Xu
Journal:  Oncotarget       Date:  2017-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.